Influence of CD34 cell selection on the incidence of mixed chimaerism and minimal residual disease after allogeneic unrelated donor transplantation

被引:8
作者
Socié, G
Cayuela, JM
Raynal, B
Esperou, H
Fund, X
Raffoux, C
Devergie, A
Ribaud, P
Marolleau, JP
Parquet, N
Sigaux, F
Brison, O
Gluckman, E
机构
[1] Hop St Louis, Serv Hematol Greffe de Moelle, F-75475 Paris 10, France
[2] Hop St Louis, Unite Rech Biol Cellules Souches, F-75475 Paris 10, France
[3] Hop St Louis, INSERM, U462, Paris, France
[4] Hop St Louis, Etablissement Transfus Sanguine, Lab Therapie Cellulaire, Paris, France
[5] Hop St Louis, France Greffe de Moelle, Paris, France
[6] Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, Villejuif, France
关键词
chimerism; residual disease; marrow transplantation; unrelated donor; T cell depletion;
D O I
10.1038/sj.leu.2401110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Marrow transplantation from unrelated donors has been linked with an increased risk of graft-versus-host disease (GVHD). In an attempt to lower the risk of acute GVHD we used CD34 marrow cell selection for T cell depletion. Since T cell depletion has been linked to an increased risk of relapse and an increased risk of marrow failure, we used PCR amplification of minisatellite sequences to investigate donor cell engraftment and RT-PCR amplification of recurrent chromosomal translocations to investigate the residual disease post-transplant. Twenty-three patients who underwent BMT after positive selection of the CD34-positive cell population were studied. Results were then compared with those of 37 patients who underwent transplantation with unmanipulated marrow graft. Among the 23 patients who received CD34(+) selected cell grafts, seven (30%) had evidence of full donor engraftment, 14 had evidence of residual recipient cells (61%), one had a non-take, and one autologous bone marrow recovery. Analysis of the chimaerism status post-transplant in 36 patients who received unmanipulated marrow grafts showed that 31 patients (86%) had evidence of full donor engraftment. The difference in the incidence of mixed chimaerism profile between patients who received unmanipulated marrow graft and those receiving CD34(+) selected cell grafts was statistically significant (P<0.01). Nine patients who received CD34(+) selected cell grafts could be analysed for the presence of minimal residual disease post-transplant (one with t(9;22) acute lymphoblastic leukaemia and eight with CML). In the patient transplanted for a Ph-positive acute leukaemia, and in two out of the eight patients with CML, the search fora fusion transcript was consistently negative after transplantation. Among the six patients with evidence of residual disease, three patients also had a mixed chimaerism profile and were given donor lymphocyte infusions. Minimal residual disease study was performed post-transplant in 16 patients who received unmanipulated marrow grafts. In 10 of 14 patients with CML, and in two patients with acute leukaemia the search for a fusion transcript was consistently negative after transplantation. The difference in the incidence of minimal residual disease between patients who received an unmanipulated marrow graft and those receiving CD34(+) selected cell grafts was not statistically significantly significant, but numbers of patients included in this analysis are still few. In conclusion, our study highlights the strong influence of graft manipulation on the incidence of mixed chimaerism after transplantation from an unrelated donor.
引用
收藏
页码:1440 / 1446
页数:7
相关论文
共 24 条
[1]  
BALDUZZI A, 1995, BLOOD, V86, P3247
[2]   UNRELATED BONE-MARROW DONOR TRANSPLANTS FOR CHILDREN WITH LEUKEMIA OR MYELODYSPLASIA [J].
CASPER, J ;
CAMITTA, B ;
TRUITT, R ;
BAXTERLOWE, LA ;
BUNIN, N ;
LAWTON, C ;
MURRAY, K ;
HUNTER, J ;
PIETRYGA, D ;
GARBRECHT, F ;
KEEVER, C ;
DROBYSKI, W ;
HOROWITZ, M ;
FLOMENBERG, N ;
ASH, R .
BLOOD, 1995, 85 (09) :2354-2363
[3]   MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - CORRELATIONS WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND RELAPSE [J].
CROSS, NCP ;
HUGHES, TP ;
FENG, L ;
OSHEA, P ;
BUNGEY, J ;
MARKS, DI ;
FERRANT, A ;
MARTIAT, P ;
GOLDMAN, JM .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (01) :67-74
[4]   EFFECT OF T-CELL DEPLETION AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS ON ENGRAFTMENT, RELAPSE, AND DISEASE-FREE SURVIVAL IN UNRELATED MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].
DROBYSKI, WR ;
ASH, RC ;
CASPER, JT ;
MCAULIFFE, T ;
HOROWITZ, MM ;
LAWTON, C ;
KEEVER, C ;
BAXTERLOWE, LA ;
CAMITTA, B ;
GARBRECHT, F ;
PIETRYGA, D ;
HANSEN, R ;
CHITAMBAR, CR ;
ANDERSON, T ;
FLOMENBERG, N .
BLOOD, 1994, 83 (07) :1980-1987
[5]   Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia [J].
Drobyski, WR ;
Endean, DJ ;
Klein, JP ;
Hessner, MJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (02) :458-466
[6]   Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia [J].
Gardiner, N ;
Lawler, M ;
ORiordan, J ;
DeArce, M ;
Humphries, P ;
McCann, SR .
BONE MARROW TRANSPLANTATION, 1997, 20 (03) :235-241
[7]   ANALYSIS OF 462 TRANSPLANTATIONS FROM UNRELATED DONORS FACILITATED BY THE NATIONAL-MARROW-DONOR-PROGRAM [J].
KERNAN, NA ;
BARTSCH, G ;
ASH, RC ;
BEATTY, PG ;
CHAMPLIN, R ;
FILIPOVICH, A ;
GAJEWSKI, J ;
HANSEN, JA ;
HENSLEEDOWNEY, J ;
MCCULLOUGH, J ;
MCGLAVE, P ;
PERKINS, HA ;
PHILLIPS, GL ;
SANDERS, J ;
STRONCEK, D ;
THOMAS, ED ;
BLUME, KG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (09) :593-602
[8]  
KOZU T, 1993, BLOOD, V82, P1270
[9]  
LANDMANPARKER J, 1994, LEUKEMIA, V8, P1989
[10]   EARLY DETECTION OF RELAPSE AFTER BONE-MARROW TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA [J].
LION, T ;
HENN, T ;
GAIGER, A ;
KALHS, P ;
GADNER, H .
LANCET, 1993, 341 (8840) :275-276